Eisai Co., Ltd. and Tokyo-based Nihon Medi-Physics Co., Ltd. have entered into a collaboration agreement to contribute to the diagnosis and treatment of dementia with Lewy bodies (DLB) in Japan. DLB is considered to be one of Japan’s three major types of dementia, alongside Alzheimer’s disease and vascular dementia.

Eisai markets Aricept (donepezil hydrochloride), a treatment approved for the suppression of progression of dementia symptoms in DLB in Japan. Based on this agreement, both companies will share with each other information on the dementia, including DLB, and work to generate new evidence as well as hold study meetings in order to improve the diagnosis and treatment of DLB.

Source: Eisai